SNIPR Biome
↗Copenhagen, Denmark
SNIPR Biome is a Copenhagen-based clinical-stage biotechnology company pioneering CRISPR-based microbial gene therapy. Founded in 2011, the company develops precision medicines that leverage the natural bacterial CRISPR-based adaptive immune system to target and kill pathogenic bacteria with high specificity. SNIPR's proprietary platform enables programmable targeting of bacteria based on their specific genomes, addressing infectious diseases and antimicrobial resistance through oral administration of engineered therapeutics. The company's novel approach treats the human microbiome as a therapeutic target organ, similar to viral gene therapy but using bacteria as delivery vehicles rather than viruses.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:CRISPR/Gene Therapy & Antimicrobial Resistance
SIZE & FINANCIALS
Employees:1-50
Founded:2011
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$139M
Investors:Lundbeckfonden BioCapital, Wellington Partners, North-East Family Office, EQT Life Sciences, Cystic Fibrosis Foundation, SPRIN-D (German Federal Agency for Breakthrough Innovation), CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), Bill & Melinda Gates Foundation, European Investment Bank
PIPELINE
Stage:Phase 1b-2a
Lead Drug Stage:Phase 1b/2a
Modalities:CRISPR/Cas Gene Therapy, Lytic Bacteriophage, Microbial Gene Therapy
Active Trials:1
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:CARB-X - Co-funding Phase 1b/2a clinical trial of SNIPR001, Cystic Fibrosis Foundation - Series B investor and CF program partner, Bill & Melinda Gates Foundation - Microbiome gene therapy platform funding, MD Anderson Cancer Center - Clinical trial collaboration for SNIPR001, SPRIN-D - German innovation agency funding and support, European Investment Bank - €20M loan for antimicrobial resistance programs, EQT Life Sciences - Investor in CRISPR technology development, IPATH - Disease research collaboration
COMPETITION
Position:Leader
Competitors:Flagship Pioneering portfolio companies (microbiome-focused), Eligo Biosciences, Seres Therapeutics, Other CRISPR therapeutics companies (Editas, CRISPR Therapeutics, Intellia), Traditional antibiotic resistance researchers
LEADERSHIP
Key Executives:
Christian Groendahl - CEO & Co-founder
Jasper Clube - Chief Intellectual Property Officer & Co-founder
Morten O.A. Sommer - Chair of Research & Co-founder
Christian E. Elling - Chairman
Stephanie Krebs - Chief Business Officer
Scientific Founders:Morten O.A. Sommer - Microbiome and CRISPR research expertise
Board Members:Christian E. Elling - Chairman
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with SNIPR Biome. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.